摘要
目的研究力达霉素辅基蛋白(idamycin apoprotein,LDP)对肿瘤细胞是否有结合作用,并考察这种结合作用与肿瘤有关生物学指标的相关性。方法用异硫氰酸荧光素酯(fluorescein isothiocyanate,FITC)与LDP进行偶联,以荧光显微镜观察此偶联物对临床常见肿瘤的荧光染色情况,按荧光强弱程度将着色结果分成阳性、可疑、阴性3级。以免疫组化法观察肿瘤生物学指标如ER,P53,Bcl-2表达情况,并将结果也分成阳性、可疑、阴性3级。以Kappa一致性检验和Spearman等级相关性检验判断相关性。结果仅部分乳腺癌显示阳性荧光着色:3例乳腺癌冰冻标本中,有2例显示阳性荧光着色;20例确诊的乳腺癌石蜡标本中,荧光染色显示阳性的11例,可疑的4例,阴性的5例。FITC-LDP偶联物对乳腺癌石蜡标本染色结果与ER、P53和Bcl-2的免疫组化染色结果分别经Kappa一致性检验,均有显著意义(P<0.05);与ER染色结果、P53染色结果和Bcl-2染色结果分别经Spearman等级相关性检验,分别呈负相关(P<0.05)、正相关(P<0.05)和无相关(P>0.05)。结论LDP对乳腺癌细胞存在特异的结合作用,这种结合作用与乳腺癌组织上的ER和突变型P53蛋白分别可能存在负相关性和正相关性。
Abstract
OBJECTIVE This experiment was set to study binding of the apoprotein to cancer cells and examine the correlation between the binding action and cancer biological index such as ER、P53、Bcl-2. METHODS LDP was linked to FITC, a fluorescent reagent. The FITC-LDP conjugate was incubated with cancer tissue specimens at a certain condition. Fluorescent microscope was used to observe fluorescent intensity of specimens. The fluorescent intensity were graded into 3 levels which included positive, doubtful and negative. The expression of cancer biological index was observed by the method of immunohistochemistry, the staining of which were also graded into 3 levels which contained positive, doubtful and negative. Kappa test or Spearman test were used to analyze the above correlation. RESULTS Only a fraction of breast cancer tissue specimen displayed positive fluorescent staining caused by FITC-LDP conjugate. 2 out of 3 iced specimens showed positive fluorescent staining. 11, 4 or 5 out of 20 wax specimens showed positive, doubtful and negative fluorescent staining, respectively. The fluorescent staining and ER, P53 or Bcl-2 immunohistochemistry staining had respective concordance with Kappa test ( P<0.05 ). The fluorescent staining and ER, P53 or Bcl-2 immunohistochemistry staining showed negative rank correlation, positive rank correlation and no rank correlation respectively with Spearman test(P<0.05). CONCLUSION LDP may have binding action on breast cancer cells, which might exist negative or positive correlation with ER or mutant P53 protein of breast cancer, respectively.
关键词
力达霉素 /
辅基蛋白 /
肿瘤组织
{{custom_keyword}} /
Key words
lidamycin /
apoprotein /
tumor tissue
{{custom_keyword}} /
王健康;孟茹松;李忠东.
抗癌药物力达霉素的辅基蛋白对肿瘤组织细胞的结合作用[J]. 中国药学杂志, 2008, 43(16): 1228-1233
WNG Jin-kng;MENG Ru-song;LI Zhong-dong.
Study on Binding of Apoprotein of Lidamycin to Cancer Cells [J]. Chinese Pharmaceutical Journal, 2008, 43(16): 1228-1233
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HU J L，XUE Y C，XIE M Y，et al. A new macromolecular antitumor antibiotics，C-1027 discovery，taxonomy of producing organism fermentation and biological activity[J] . Antibiotics，1988，41(11)：1575-1579.
[2] OTANI T，MINAMI Y，MARUNAKA T，et al. A new macromolecular antitumor antiobiotic，C-1027 isolation and physico-chemical properties[J] . Antibiotics，1988，41 (11) ：1580-1585.
[3] ZHEN Y S，MING X Y，YU B，et al. A new macromolicular antitumor antibiotic，C-1027. Antitumor activity[J] . Antibiotics，1989，42 (8)：1294-1298.
[4] SUGIURA Y，MATSUMOTO T. Some characteristics of DNA strand scission by macro-molecular antitumor antibiotic C-1027 containing a novel enediyne chromophore[J] . Biochemistry，1993，32(21)：5548-5553.
[5] XU Y J，ZHEN Y S ，GOLDBERG I H. C1027 chromophore，a potent new enediyne antitumor antibiotic，induces sequence-specific double-strand DNA cleavage[J] . Biochemistry，1994，33(19)：5947-5954.
[6] SUN Y W，LI D D，ZHEN Y S. Advances in antitumor research of C1027，an enediyne macromolecular antitumor antibiotics[J] . Pharm Biotech(药物生物技术)，1998，5（4）：252-256.
[7] SHAO R G， ZHEN Y S. Study progresses of high effective enediyne antibiotic[J] . World Notes Antibiot(国外医药·抗生素分册)，1995，16(3) ：194-199.
[8] ZHEN Y ，XUE Y C，SHAO R G. Antitumor activity of the new enediyne antibiotic C1027[J] . Chin J Antibio(中国抗生素杂志)，1994，19(2)：164-168.
[9] OTANI T，YASUHARA T，MINAMI Y，et al. Purification and primary structure of C-1027-AG，a selective anagonist of antitumor antibiotic C-1027 from Strptomyces globisporus[J] . Agric Biol Chem，1991，55(2)：407-419.
[10] RUAN Y B. Immuno-Flurescent Foundation. Experimental New Principle and Its Clinical New Application（免疫荧光基础. 实验新原理和它的临床新应用）[M] . Beijing：People’s Medical Publishing House，2000：8-76.
[11] PEI J，YU C J，WANG B Z，et al. Study of expression and clinicopathologic correlation of ER、PR、HER-2 in postmenopausal women with breast invasion ductal carcinoma[J] . Acta Univ Med Anhui（安徽医科大学学报），2005，40（1）：41-43.
[12] SPEIRS V，KERIN M J. Prognostic significance of estrogen receptor beta in breast cancer[J] . Br J Surg，2000，87(4)：405-409.
[13] VASCONCELOS A，MEDEIROS R，VEIGA L，et al. Analysis of estrogen receptor，polymorphism in codon 325 by PCR-SSCP in breast cancer：association with lymph node metastasis[J] . Breast J，2002，8(4)：226-229.
[14] LIU Y H，QIU Y. Application of immunocyte chemical assay in the diagnosis and treatment of breast cancer[J] .Foreign Med Sci (Cancer Sec)(国外医学·肿瘤学分册)，2000，27(3)：165-167.
[15] MIRZA A，MCGUIRK M，HOCKENBERRY T N，et al. Humansur-vivin is negatively regulated by wildtype p53 and participates in p53 dependent apoptotic pathway[J] . Oncogene，2002，21(17)：2613-2622.
[16] WASIELEWSKI M ，ELSTRODT F，KLIJN J G，et al. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines[J] . Breast Cancer Res Treat，2006，99(1) ：20-22.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
